RU2015128024A - Фармацевтическая композиция на основе хлорпрокаина для повторного интратекального введения - Google Patents
Фармацевтическая композиция на основе хлорпрокаина для повторного интратекального введения Download PDFInfo
- Publication number
- RU2015128024A RU2015128024A RU2015128024A RU2015128024A RU2015128024A RU 2015128024 A RU2015128024 A RU 2015128024A RU 2015128024 A RU2015128024 A RU 2015128024A RU 2015128024 A RU2015128024 A RU 2015128024A RU 2015128024 A RU2015128024 A RU 2015128024A
- Authority
- RU
- Russia
- Prior art keywords
- use according
- chlorprocaine
- chlorprocain
- hcl
- aqueous solution
- Prior art date
Links
- 238000007913 intrathecal administration Methods 0.000 title claims 4
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 6
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 claims 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 4
- 239000007864 aqueous solution Substances 0.000 claims 4
- 229960002023 chloroprocaine Drugs 0.000 claims 4
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical group CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- 206010002091 Anaesthesia Diseases 0.000 claims 1
- 230000037005 anaesthesia Effects 0.000 claims 1
- 230000000202 analgesic effect Effects 0.000 claims 1
- 239000000730 antalgic agent Substances 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 229940127240 opiate Drugs 0.000 claims 1
- 229960005489 paracetamol Drugs 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 239000008223 sterile water Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
- A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (10)
1. Применение хлорпрокаина или его солей для производства инъекционного фармацевтического водного раствора, не содержащего консервирующих веществ и антиоксидантов, имеющего значение pH от 3 до 4 и предназначенного для центральной локорегионарной анестезии у людей с помощью интратекального введения, по меньшей мере, дозы 15-80 мг в день повторно в течение периода времени от 2 до 10 дней.
2. Применение по п. 1, при котором указанная соль хлорпрокаина представляет собой хлорпрокаин HCl.
3. Применение по п. 1, включающее интратекальное введение суточной дозы 30-60 мг хлорпрокаина или его соли.
4. Применение по п. 1, при котором интратекальное введение включает введение суточной дозы повторно в течение периода времени от 3 до 7 дней.
5. Применение по п. 1, при котором инъекционный фармацевтический водный раствор содержит хлорпрокаин HCl, хлорид натрия, стерильную воду и хлористоводородную кислоту.
6. Применение по п. 1, при котором инъекционный фармацевтический водный раствор содержит количество хлорпрокаина от 0,5 до 1,5% по весу.
7. Применение по п. 1, при котором инъекционный фармацевтический водный раствор содержит 5-15 мг хлорпрокаина HCl/мл воды, 4-12 мг NaCl и HCl в количестве, достаточном для достижения значения pH 3,0-4,0.
8. Применение по п. 1, при котором указанный хлорпрокаин вводится в комбинации с адреналином в повторных дозах.
9. Применение по п. 1, при котором указанный хлорпрокаин вводится в комбинации с анальгетическим средством в повторных дозах.
10. Применение по п. 9, при котором указанное анальгетическое средство выбирают из ацетаминофена, NSAID, кортикостероидов, опиатных лекарственных средств и их смесей.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITMI2012A002120 | 2012-12-12 | ||
| IT002120A ITMI20122120A1 (it) | 2012-12-12 | 2012-12-12 | Composizione farmaceutica a base di cloroprocaina per la somministrazione intratecale ripetuta |
| PCT/IB2013/060801 WO2014091420A1 (en) | 2012-12-12 | 2013-12-11 | Chloroprocaine-based pharmaceutical composition for repeated intrathecal administration |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2015128024A true RU2015128024A (ru) | 2017-01-18 |
| RU2648823C2 RU2648823C2 (ru) | 2018-03-28 |
Family
ID=47633206
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015128024A RU2648823C2 (ru) | 2012-12-12 | 2013-12-11 | Фармацевтическая композиция на основе хлорпрокаина для повторного интратекального введения |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9504666B2 (ru) |
| KR (1) | KR102162587B1 (ru) |
| CN (1) | CN105283222A (ru) |
| AR (1) | AR099443A1 (ru) |
| AU (1) | AU2013356855B2 (ru) |
| IL (1) | IL239270B (ru) |
| IT (1) | ITMI20122120A1 (ru) |
| MX (1) | MX2015007288A (ru) |
| MY (1) | MY180957A (ru) |
| NZ (1) | NZ709631A (ru) |
| PH (1) | PH12015501313A1 (ru) |
| RU (1) | RU2648823C2 (ru) |
| SG (1) | SG11201504572WA (ru) |
| UA (1) | UA115078C2 (ru) |
| WO (1) | WO2014091420A1 (ru) |
| ZA (1) | ZA201504618B (ru) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020002898A (es) * | 2017-09-15 | 2020-11-06 | Sintetica S A | Formulaciones topicas de cloroprocaina y metodos para utilizar las mismas. |
| CN111494310A (zh) * | 2020-04-29 | 2020-08-07 | 周晓玲 | 一种局部麻醉药物的制备及使用方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1572218A4 (en) * | 2002-12-20 | 2007-05-16 | Univ Leland Stanford Junior | LOCAL ANESTHETICS WITH ESTER COMBINATION |
| ITMI20051633A1 (it) * | 2005-09-06 | 2007-03-07 | Sint Sa | Nuovo uso di una composizione comprendente cloroprocaina hcl nuova composizione comprendente cloroprocaina hcl e metodo per la sua fabbricazione |
-
2012
- 2012-12-12 IT IT002120A patent/ITMI20122120A1/it unknown
-
2013
- 2013-12-09 AR ARP130104578A patent/AR099443A1/es unknown
- 2013-12-11 SG SG11201504572WA patent/SG11201504572WA/en unknown
- 2013-12-11 MX MX2015007288A patent/MX2015007288A/es unknown
- 2013-12-11 NZ NZ709631A patent/NZ709631A/en unknown
- 2013-12-11 MY MYPI2015701905A patent/MY180957A/en unknown
- 2013-12-11 WO PCT/IB2013/060801 patent/WO2014091420A1/en not_active Ceased
- 2013-12-11 UA UAA201506088A patent/UA115078C2/uk unknown
- 2013-12-11 AU AU2013356855A patent/AU2013356855B2/en active Active
- 2013-12-11 RU RU2015128024A patent/RU2648823C2/ru active
- 2013-12-11 US US14/650,583 patent/US9504666B2/en active Active
- 2013-12-11 CN CN201380065146.8A patent/CN105283222A/zh active Pending
- 2013-12-11 KR KR1020157018300A patent/KR102162587B1/ko active Active
-
2015
- 2015-06-07 IL IL239270A patent/IL239270B/en active IP Right Grant
- 2015-06-09 PH PH12015501313A patent/PH12015501313A1/en unknown
- 2015-06-25 ZA ZA2015/04618A patent/ZA201504618B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2013356855B2 (en) | 2018-02-15 |
| MY180957A (en) | 2020-12-14 |
| SG11201504572WA (en) | 2015-07-30 |
| PH12015501313B1 (en) | 2015-08-24 |
| US20150320716A1 (en) | 2015-11-12 |
| RU2648823C2 (ru) | 2018-03-28 |
| UA115078C2 (uk) | 2017-09-11 |
| MX2015007288A (es) | 2015-09-10 |
| NZ709631A (en) | 2020-03-27 |
| KR20150085131A (ko) | 2015-07-22 |
| AR099443A1 (es) | 2016-07-27 |
| ITMI20122120A1 (it) | 2014-06-13 |
| IL239270B (en) | 2018-03-29 |
| WO2014091420A1 (en) | 2014-06-19 |
| US9504666B2 (en) | 2016-11-29 |
| PH12015501313A1 (en) | 2015-08-24 |
| CN105283222A (zh) | 2016-01-27 |
| IL239270A0 (en) | 2015-07-30 |
| ZA201504618B (en) | 2019-01-30 |
| AU2013356855A1 (en) | 2015-07-23 |
| KR102162587B1 (ko) | 2020-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210343T1 (hr) | Soli ili ko-kristali 3-(3-dimetilamino-1-etil-2-metil-propil)-fenola | |
| JP2013520405A5 (ru) | ||
| ME02477B (me) | Genz 112638 za lečenje gošeove ili fabrijeve bolesti u kombinacionoj terapiji | |
| JP2016106150A5 (ru) | ||
| JP2015518818A5 (ru) | ||
| BR112014016085A2 (pt) | composições aprimoradas e métodos para distribuição de omeprazol mais ácido acetilsalicílico | |
| NZ714963A (en) | Compositions and methods for treating anemia | |
| PH12016501342A1 (en) | Intranasal pharmaceutical dosage forms comprising naloxone | |
| AR082150A1 (es) | N-etil-n-fenil-1,2-dihidro-4-hidroxi-5-cloro-1-metil-2-oxoquinolin-3-carboxamida deuterada, sales y usos de la misma, metodo de tratamiento, mezcla compuestos, composicion farmaceutica, proceso de preparacion, compuesto enriquecido con deuterio | |
| JP2015517488A5 (ru) | ||
| HK1221646A1 (zh) | 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途 | |
| PE20142319A1 (es) | Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero | |
| JP2016185995A5 (ru) | ||
| MX2020010300A (es) | Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas. | |
| JP2013541583A5 (ru) | ||
| EA201992382A3 (ru) | Пероральная таблетированная фармацевтическая композиция двойного применения на основе сульфатных солей и способы ее применения | |
| RU2015128024A (ru) | Фармацевтическая композиция на основе хлорпрокаина для повторного интратекального введения | |
| MX2018005298A (es) | Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa. | |
| CO2018009543A2 (es) | Composición farmacéutica de liberación prolongada que comprende cisteamina o sal de la misma | |
| TN2016000179A1 (en) | Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor. | |
| RU2014148062A (ru) | Инъекционная фармацевтическая композиция декскетопрофена и трамадола | |
| JP2015533131A5 (ru) | ||
| RU2016144342A (ru) | Стабильные композиции нейроактивных пептидов | |
| UA120764U (uk) | Лікарський препарат знеболювальної та спазмолітичної дії "фентаніл" | |
| RU2022102814A (ru) | Комбинация ибупрофена и трамадола для уменьшения боли |